We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$40.7B
AUM Growth
-$4.56M
(-0.01%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
19.9%
Holding
801
New
88
Increased
169
Reduced
396
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$165M |
| 2 |
Costco
COST
|
+$134M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$126M |
| 4 |
Johnson Controls International
JCI
|
+$121M |
| 5 |
3M
MMM
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$136M |
| 3 |
Marathon Petroleum
MPC
|
+$123M |
| 4 |
CenterPoint Energy
CNP
|
+$123M |
| 5 |
Under Armour
UAA
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.42% |
| 2 | Healthcare | 16.85% |
| 3 | Financials | 12.9% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Industrials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Douglas Emmett
DEI
$1.98B
| $5.52M | 0.01% |
+125,698
| New | +$5.44M |
|
|
HBI
602
DELISTED
Hanesbrands
HBI
| $5.49M | 0.01% |
369,721
-2,042,478
| -85% | -$31M |
|
603
Bread Financial
BFH
$4.37B
| $5.3M | 0.01% |
59,239
-2,722
| -4% | -$240K |
|
604
CACI
CACI
$11B
| $5.29M | 0.01% |
21,167
-105,200
| -83% | -$24.5M |
|
605
H&R Block
HRB
$5.58B
| $5.28M | 0.01% |
224,700
-10,800
| -5% | -$259K |
|
606
Labcorp
LH
$25B
| $5.23M | 0.01% |
35,968
-99,405
| -73% | -$14.4M |
|
607
Equifax
EFX
$20.3B
| $5.2M | 0.01% |
37,100
-106,700
| -74% | -$14.8M |
|
|
VAPO
608
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $5.17M | 0.01% |
53,125
-67,361
| -56% | -$5.69M |
|
|
PROS
609
DELISTED
ProSight Global, Inc.
PROS
| $5.1M | 0.01% |
316,353
-5,997
| -2% | -$101K |
|
610
Kinetik
KNTK
$3.72B
| $5.07M | 0.01% |
177,410
+125,000
| +239% | +$2.88M |
|
|
MXIM
611
DELISTED
Maxim Integrated Products
MXIM
| $5.04M | 0.01% |
+82,000
| New | +$4.78M |
|
612
Cathay General Bancorp
CATY
$4.22B
| $4.95M | 0.01% |
130,000
-10,000
| -7% | -$366K |
|
|
TVRD
613
Tvardi Therapeutics
TVRD
$19.7M
| $4.95M | 0.01% |
8,528
-5,555
| -39% | -$3.9M |
|
614
Pentair
PNR
$10.4B
| $4.91M | 0.01% |
106,952
-884,300
| -89% | -$37.4M |
|
|
PRSP
615
DELISTED
Perspecta Inc. Common Stock
PRSP
| $4.82M | 0.01% |
182,168
-115,000
| -39% | -$3.06M |
|
|
AIV
616
Aimco
AIV
$387M
| $4.67M | 0.01% |
679,373
+39,876
| +6% | +$282K |
|
617
Cardinal Health
CAH
$53.9B
| $4.67M | 0.01% |
92,400
-266,200
| -74% | -$13.7M |
|
618
Expro Ltd
XPRO
$1.79B
| $4.55M | 0.01% |
146,808
+16,667
| +13% | +$510K |
|
619
CrowdStrike
CRWD
$194B
| $4.49M | 0.01% |
360,000
+260,000
| +260% | +$3.41M |
|
620
Henry Schein
HSIC
$9.77B
| $4.47M | 0.01% |
67,000
-8,100
| -11% | -$536K |
|
621
Chewy
CHWY
$9.25B
| $4.35M | 0.01% |
150,000
| – | – |
|
622
Enovis
ENOV
$1.68B
| $4.25M | 0.01% |
+67,862
| New | +$3.84M |
|
|
VRAY
623
DELISTED
ViewRay, Inc.
VRAY
| $4.22M | 0.01% |
+1,000,000
| New | +$3.23M |
|
624
Datadog
DDOG
$95.4B
| $4.16M | 0.01% |
110,000
-140,000
| -56% | -$5.04M |
|
625
International Flavors & Fragrances
IFF
$20.2B
| $4.06M | 0.01% |
31,501
-98,199
| -76% | -$12.5M |
|
Similar funds
Adage Capital Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Adage Capital Partners held 801 positions worth $40.7B, down 0.01% from $40.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Adage Capital Partners withdrew a net $3.46B in Q4 2019, closing 90 positions and reducing 396 holdings. Its most notable exit was Celgene Corp, an estimated $1.48B position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $142M.
- Adage Capital Partners's largest Q4 2019 buy was Bristol-Myers Squibb: 2,207,539 shares worth $142M.
- Adage Capital Partners added most to RTX Corp in Q4 2019, an estimated $165M increase.
- Adage Capital Partners's biggest Q4 2019 reduction was Apple, cutting an estimated $136M.
- Adage Capital Partners fully exited Celgene Corp in Q4 2019, selling an estimated $1.48B.
- Adage Capital Partners's ten largest holdings make up 20% of its $40.7B portfolio in Q4 2019.
- Adage Capital Partners opened 88 new positions and closed 90 in Q4 2019.
- Adage Capital Partners's portfolio value fell 0.01% quarter-over-quarter to $40.7B.
Based on Adage Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.